Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating osteocalcin during oral anticoagulant therapy.

L J van Haarlem1, M H Knapen, K Hamulyák

  • 1Department of Biochemistry, University of Limburg, Maastricht, The Netherlands.

Thrombosis and Haemostasis
|August 30, 1988
PubMed
Summary

Vitamin K antagonists decrease serum osteocalcin levels and its binding to hydroxyapatite in both sheep and humans. Vitamin K counteracts anticoagulant effects but not these changes in osteocalcin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study.

European journal of clinical nutrition·2017
Same author

Reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary phylloquinone and menaquinones.

European journal of clinical nutrition·2017
Same author

The impact of a male or female thrombotic family history on contraceptive counseling: a cohort study.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Steady-state vitamin K2 (menaquinone-7) plasma concentrations after intake of dairy products and soft gel capsules.

European journal of clinical nutrition·2016
Same author

Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial.

The journal of nutrition, health & aging·2016
Same author

Vitamin K Status Is not Associated with Cognitive Decline in Middle Aged Adults.

The journal of nutrition, health & aging·2015

Area of Science:

  • Biochemistry
  • Pharmacology
  • Bone Metabolism

Background:

  • Osteocalcin (bone Gla-protein) is a vitamin K-dependent protein crucial for bone mineralization.
  • Vitamin K antagonists are widely used as anticoagulants.
  • The effect of vitamin K antagonists on osteocalcin metabolism is not fully understood.

Purpose of the Study:

  • To investigate the impact of vitamin K antagonists on serum osteocalcin levels and its hydroxyapatite binding affinity.
  • To determine if vitamin K can counteract these effects.

Main Methods:

  • Administration of vitamin K antagonists (phenprocoumon) to sheep.
  • Administration of vitamin K to sheep treated with phenprocoumon.
  • Measurement of serum osteocalcin levels and hydroxyapatite binding affinity in sheep.

Related Experiment Videos

  • Observation of vitamin K antagonist effects in human subjects.

    • Main Results:

    • In sheep, phenprocoumon decreased serum osteocalcin levels and its affinity for hydroxyapatite.
    • Vitamin K counteracted phenprocoumon's effect on blood coagulation but not on osteocalcin production in sheep.
    • In humans, vitamin K antagonists similarly reduced serum osteocalcin and its hydroxyapatite affinity.
    • These changes reached steady-state within 24 hours and persisted for years during oral anticoagulant therapy.

    Conclusions:

    • Vitamin K antagonists significantly impact osteocalcin metabolism, reducing both serum levels and hydroxyapatite binding affinity.
    • Vitamin K does not reverse these effects on osteocalcin, despite counteracting anticoagulant activity.
    • These findings highlight a potential dissociation between the anticoagulant and bone-related effects of vitamin K antagonists.